Clinical Trials Logo

Filter by:
NCT ID: NCT05201885 Recruiting - Rectum Cancer Clinical Trials

Oncological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer.

Start date: January 15, 2022
Phase:
Study type: Observational

The primary purpose of this study is to compare the differences of oncological in rectal cancer patients undergoing laparoscopic or transanal endoscopy radical resection. The secondary purpose is to compare the effect of two different surgical methods on prognosis.

NCT ID: NCT05201872 Recruiting - Rectum Cancer Clinical Trials

Bacteriological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer.

Start date: January 15, 2022
Phase:
Study type: Observational

The primary purpose of this study is to compare the differences of bacteriological in rectal cancer patients undergoing laparoscopic or transanal endoscopy radical resection. The secondary purpose is to compare the effects of two different surgical methods on postoperative complications.

NCT ID: NCT05201859 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Start date: March 29, 2022
Phase: Phase 2
Study type: Interventional

This randomized clinical trial determining whether Sintilimab plus Capecitabine versus Capecitabine alone can improve the progression-free survival rate of NPC patients with unfavorable response to induction chemotherapy. Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST1.1 after two cycles induction chemotherapy will have concurrent chemoradiotherapy. MRI, CT and EBV DNA will be assessed before the end of radiotherapy. After concurrent chemoradiotherapy, eligible patients will be randomized to receive either adjuvant Sintilimab plus Capecitabine or Capecitabine alone.

NCT ID: NCT05201781 Recruiting - Multiple Myeloma Clinical Trials

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Start date: March 9, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

NCT ID: NCT05201729 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma, PDAC

Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer

Start date: August 1, 2021
Phase:
Study type: Observational

The early diagnosis rate of pancreatic cancer is low and most patients rely on palliative chemotherapy. However, the clinical benefit and objective response rate (ORR) of patients with first-line chemotherapy are low. Therefore,it is essential to develop new therapies to improve the survival of patients with pancreatic cancer.

NCT ID: NCT05201677 Recruiting - High Myopia Clinical Trials

Improved Operation of Low Intraocular Pressure in Phacoemulsification for Patients With High Myopia Complicated With Cataract

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Approximately 60 participants at Eye Hospital of Wenzhou Medical University during October,2021 to January 2022 will be enroll in the investigators' study. And dived them randomly into 2 groups:High myopia with axial length between 26 mm and 28 mm and High myopia with axial length more than 28 mm (30 eyes) .

NCT ID: NCT05201599 Recruiting - Urinary Calculi Clinical Trials

Treatment of Upper Urinary Tract Stones With a Diameter≤2cm by Intelligent Pressure-controlled Flexible Ureteroscope

Start date: August 11, 2021
Phase: N/A
Study type: Interventional

The aim of this trial is to compare the efficacy and safety of flexible ureteroscope with intelligent control of renal pelvic pressure (FURL-ICP) and traditional flexible ureteroscope(f-URL) in the treatment of upper urinary stones ≤ 2cm in diameter. It is designed as a multicenter, parallel randomized controlled trial with two arms. At least 449 patients with upper urinary stones ≤ 2cm in diameter will be invited to participant in this study. Patients will be assigned to intervention group (FURL-ICP group) or control group (f-URL) by a simple random sampling technique with a rate of 1:1. The baseline of participants include demographic data, urine analysis, blood cell analysis, blood biochemical analysis, and urinary computer tomography (CT) with a slice thickness of 2mm. The primary outcomes are postoperative stone-free rate (SFR) of one month by CT scan and postoperative fever rate (body temperature > 38.5 ℃ within 3 days after operation). Secondary outcomes include operating time, degree of ureteral injury, SFR of one day.

NCT ID: NCT05201430 Recruiting - Rectal Cancer Clinical Trials

Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

RCNAC
Start date: August 27, 2021
Phase: Phase 3
Study type: Interventional

This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer. This study aims to optimize the neoadjuvant therapy for patients with anus-preserving resectable locally advanced rectal cancer, so as to improve the prognosis of them. It remains unclear about whether FOLFOXIRI or CapeOX neoadjuvant chemotherapy is more effective for locally advanced rectal cancer.

NCT ID: NCT05201326 Recruiting - Clinical trials for Recurrent Glioblastoma

Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

Start date: December 22, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I study to observe the safety and efficacy of irinotecan and bevacizumab combined with re-radiotherapy in the treatment of recurrent glioblastoma. The study will provide a higher level of clinical evidence-based evidence for the clinical treatment of recurrent GBM, and fill the guidelines for the treatment of recurrent GBM.

NCT ID: NCT05201274 Recruiting - AMI Clinical Trials

Baduanjin Sequential Therapy and Cardiac Function of AMI With Reduced EF After PCI

BST-AMI
Start date: November 11, 2021
Phase: N/A
Study type: Interventional

Acute myocardial infarction (AMI) is one of the leading causes of death around the world, with the potential for substantial morbidity and mortality. The increasing evidence indicates that exercise training has beneficial effects on LV remodelling in post-MI patients with greater benefits occurring when training earlier following MI, among which the earliest time for rehabilitation is one week after myocardial infarction. However, the effect of Baduanjin sequential therapy for patients after one week of AMI has yet to be assessed. Therefore, the aim of this study is to assess the impact of Baduanjin sequential therapy on cardiac and physical function in patients with AMI and reduced ejection fraction after primary PCI.